Introduction
Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion protein is an oncogenic driver for approximately 5% of non-small-cell lung cancer (NSCLC) patients [1] . Crizotinib is an orally active ALK tyrosine kinase inhibitor which has shown marked antitumor activity in NSCLC patients who harbor EML4-ALK [2] . Among the patients who are treated with tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR-TKI), some experience rapid disease progression after discontinuation of EGFR-TKI [3] . However, this phenomenon, known as disease flare, has not been well described in patients treated with ALK inhibitor. Here, we report a case of disease flare after discontinuation of crizotinib.
Case Report
A 50-year-old male former smoker was found to have a left lung nodule, 25 mm in size, and chest computed tomography (CT) revealed lymph node metastases in the left hilum and mediastinum. Endobronchial ultrasound transbronchial aspiration demonstrated adenocarcinoma, and he was diagnosed with lung cancer (T1bN2M0). Two cycles of cisplatin and vinorelbine chemotherapy were administered concurrently with 50 Gy thoracic irradiation. He underwent left lower lobe resection and then received 4 cycles of adjuvant chemotherapy with carboplatin and paclitaxel; however, a single pulmonary metastasis was detected in the right lower lobe, and he received 48 Gy stereotactic radiotherapy. Subsequently, he developed mediastinal lymph node metastases. Fluorescent in situ hybridization analysis revealed that his tumor had an EML4-ALK rearrangement. The administration of crizotinib (500 mg/day) was initiated. A partial response was achieved and maintained for 10 months ( fig. 1a ); however, regrowth of the mediastinal lymph nodes was confirmed ( fig. 1b ). Crizotinib was continued for 1 month, and the size of the lymph nodes increased slightly ( fig.  1c ). At that time, crizotinib was discontinued and he participated in a randomized doubleblinded phase III study of erlotinib ± Met inhibitor. Chest CT before the start of the experimental therapy (2 weeks after discontinuation of crizotinib) showed evident increase of the mediastinal lymph nodes but he did not complain of any symptoms ( fig. 1d ). However, 1 week after the start of the experimental therapy (3 weeks after discontinuation of crizotinib), he started to complain of dyspnea and dysphagia, and chest CT revealed a marked increase of the mediastinal lymph nodes accompanying marked stenosis of the bronchus and esophagus (5 weeks after discontinuation of crizotinib) ( fig. 1e ). The diagnosis of disease flare was made and readministration of crizotinib was started immediately. However, his disease progressed rapidly, and he died 2 days after starting crizotinib retreatment.
Discussion
It has been recognized that some tumor cells remain sensitive to EGFR-TKI even after disease progression and that some patients experience acute exacerbation, known as disease flare, after withdrawal of EGFR-TKI [3] . However, no such phenomenon had been reported in patients treated with ALK inhibitor until recently [4] . To our knowledge, this is the second case report of disease flare in ALK-positive NSCLC.
Although there has been no clear explanation of the mechanism of disease flare, some data have indicated that the indolent nature of T790M-mediated resistance may be partly responsible for the phenomenon in patients treated with EGFR-TKI [5] . However, the incidence of disease flare is unknown, and it is practically impossible to predict who will and will not experience disease flare after discontinuation of EGFR-TKI. This is also true for ALK inhibitor.
Although readministration is reportedly effective for disease flare after discontinuation of EGFR-TKI [6] and maybe after ALK inhibitor, rapid disease progression may deprive the patients of a second chance, as in our case. Therefore, continuing EGFR-TKI or ALK inhibitor after disease progression may be a reasonable option to avoid disease flare, and a prospective study is mandatory to verify this concept.
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